Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age10+
SponsorUniversity Children's Hospital, Zurich

About this trial

Treatment of PKU implies for most patients that with strict adherence to dietary treatment they can achieve excellent neurocognitive outcome. Dietary treatment, though, is hard to comply to every day and with every single meal. Unsurprisingly, health-related quality of life (HrQol) is negatively affected if patients have to follow a dietary regime of this kind. Adherence to treatment in PKU is very variable. Factors of significant impact on adherence to treatment and well-being in chronic disease such as self-efficacy or parenting stress have not yet been widely investigated in PKU patients.

The ideal treatment prescription (and guideline) recommends as much as necessary and as little as possible, based on the best evidence available. Patients should neither be deprived of treatment options nor be exposed to overtreatment.

This study investigates adherence, metabolic control, HrQol in PKU patients treated by centres which follow different guidelines

Eligibility criteria

Qualifiers

Patients with PKU from age 10 years requiring dietary and / or pharmacological treatment according to locally applied guidelines

Parents of patients with PKU aged 10 to 18 years requiring dietary and / or pharmacological treatment according to locally applied guidelines

Ability and willingness to answer the questionnaires and follow the study procedures

Informed consent as documented by signature

Disqualifiers

Inability to follow the procedures of the study, e.g. due to language problems or severely reduced health status

Pregnant patients or patients who have disclosed to their physician that they are planning a pregnancy in the near future

Hyperphenylalaninaemia or mild forms of PKU or other inborn errors associated with elevated Phe but not requiring dietary and / or pharmacological treatment according to locally applied guidelines

No inform

Trial design

Treatments tested in this trial

  • no intervention

Treatment groups

No treatment groups listed

Sponsors and collaborators

University Children's Hospital, Zurich

Lead sponsor

UChildrenVienna

Collaborator

University Children's Hospital Basel

Collaborator

Insel Gruppe AG, University Hospital Bern

Collaborator